Fibric Acid Antilipemic Agents


Article Author:
Christin Mathew


Article Editor:
Paramvir Singh


Editors In Chief:
Kranthi Sitammagari
Mayank Singhal


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes


Updated:
3/22/2019 1:03:53 AM

Indications

Fibric acids are FDA indicated to treat patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb). They reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol, triglycerides, and apolipoprotein B, and increase high-density lipoprotein cholesterol (HDL-C) in adults. Fibric acids should be used in conjunction with a restriction of cholesterol and fat intake and exercise if the response to diet and nonpharmacological interventions alone has been inadequate. Secondary causes of hyperlipidemia should be ruled out before initiating therapy with a fibric acid. The therapy should be administered for at least 2 to 3 months before assessing for efficacy. Fibric acid derivatives are also FDA indicated to treat adults who have high levels of serum triglycerides (Fredrickson types IV and V). Hypertriglyceridemia manifests itself in cardiovascular disease and pancreatitis.[1] 

Mechanism of Action

Fibric acids are peroxisome proliferator-activated receptors alpha (PPAR-alpha) agonists. Fibric acids act as ligands that bind to PPAR-alpha. PPAR-alpha is a ligand-activated transcriptional factor that belongs to the family of nuclear receptors. Once activated, PPAR-alpha is in charge of several biological functions including fatty acid beta-oxidation and lipid metabolism. By binding to PPAR-alpha, fibric acids reduce blood cholesterol by increasing fatty acid oxidation, elimination of triglyceride-rich particles, and the catabolism of very-low-density lipoproteins (VLDL). The decrease in VLDL can cause plasma triglyceride levels to decrease by 30 to 60%. Additionally, fibric acids have been shown to work at the vascular wall in an anti-inflammatory and anti-thrombotic capacity. Fibric acids have pleiotropic effects that work to reduce atherosclerotic plaque formation, and thus, decrease the incidence of cardiovascular complications including coronary heart disease (CHD).[2] 

Administration

In the class of fibric acids, there are three agents of choice: fenofibric acid, fenofibrate, and gemfibrozil. All of these agents are administered orally as either tablets or capsules. Fenofibric acid and fenofibrate are each marketed under several different trade names and available in different strengths. In regards to the difference between the two, fenofibrate is the choline salt of fenofibric acid. Fenofibric acid is more hydrophilic and has a better bioavailability than its choline salt counterpart.[3] Fenofibrate and fenofibric acid are each dosed once daily without regard to meals.

Gemfibrozil

  • The recommended adult dose is 1200 mg administered as two divided doses 30 minutes before morning and evening meals. 

Worsening renal insufficiency is an issue upon the addition of gemfibrozil therapy in patients with a baseline serum creatinine of 2.0 mg/dl.

For Severe Renal Impairment: Contraindicated

Fenofibrate

For Hypercholesterolemia or Mixed Dyslipidemia: 

  • The initial dose is 145 mg once daily. 

For Severe Hypertriglyceridemia  

  • The starting dose is 48 to 145 mg once daily.
    • Doses should be individualized according to patient response and should be adjusted if necessary following lipid determinations at 4 to 8-week intervals.   

For Mild to Moderate Renal Impairment: Dose should be initiated at 48 mg and increased only after evaluation of the effects on renal function and lipid levels. 

For Severe Renal Impairment: Contraindicated

Fenofibric acid

Co-administration Therapy with Statin for the Treatment of Mixed Dyslipidemia

  • The dose is 135 mg once daily, taken at the same time as a statin.

For Severe Hypertriglyceridemia

  • The initial dose is 45 to 135 mg once daily.

For Primary Hyperlipidemia or Mixed Dyslipidemia: 

  • The dose is 135 mg once daily.

For Mild to Moderate Renal Impairment: Dose should be initiated at 45 mg and increased only after evaluation of the effects on renal function and lipid levels. 

For Severe Renal Impairment: Contraindicated

Adverse Effects

Adverse effects of fibric acids vary depending on the particular agent selected for the patient. Some of the most common adverse effects include a headache, dizziness, back pain, diarrhea, dyspepsia, nasopharyngitis, sinusitis, and abnormal liver function tests. Comparatively, gemfibrozil is associated with a more significant percentage of gastrointestinal reactions (34.2%) including dyspepsia, abdominal pain, and acute appendicitis. Fenofibrate may be a more suitable agent in patients with a past medical history significant for gastrointestinal diseases. However, fenofibrate is associated with a statistically significant increase in liver transaminases (7.5%), which requires monitoring in patients initiating therapy.

Gemfibrozil

  • Gastrointestinal reactions (34.2%)
    • Dyspepsia (19.6%)
    • Abdominal pain (9.8%)
    • Acute appendicitis (1.2%)
  • Atrial fibrillation (0.7%)

Adverse events reported without statistical significance vs. placebo:

  • Diarrhea (7.2%)
  • Fatigue (3.8%)
  • Nausea/vomiting (2.5%)
  • Eczema (1.9%)
  • Rash (1.7%)
  • Vertigo (1.5%)
  • Constipation (1.4%)
  • Headache (1.2%)

Fenofibrate

  • Body as a Whole
    • Abdominal pain (4.6%)
    • Back pain (3.4%)
    • Headache (3.2%)
  • Digestive
    • Nausea (2.3%)
    • Constipation (2.1%)
  • Metabolic and Nutritional Disorders
    • Abnormal liver function tests (7.5%)
    • Increased ALT (3.0%)
    • Increased CPK (3.0%)
    • Increased AST (3.4%)
  • Respiratory
    • Respiratory disorder (6.2%)
    • Rhinitis (2.3%)

Fenofibric acid

  • Gastrointestinal Disorders
    • Constipation (3.3%)
    • Diarrhea (3.9%)
    • Dyspepsia (3.7%)
    • Nausea (4.3%)
  • General Disorders and Administration Site Conditions
    • Fatigue (2.0%)
    • Pain (3.5%)
  • Investigations
    • ALT increased (1.2%)
  • Musculoskeletal and Connective Tissue Disorders
    • Arthralgia (3.9%)
    • Back pain (6.3%)
    • Muscle spasms (1.6%)
    • Myalgia (3.3%)
    • Pain in extremity (4.5%)
  • Infections and Infestations
    • Nasopharyngitis (3.5%)
    • Sinusitis (3.3%)
    • Upper respiratory tract infection (5.3%)
  • Nervous System Disorders
    • Dizziness (4.1%)
    • Headache (12.7%)

Contraindications

Contraindications for the use of fibric acids include a history of hypersensitivity to the drugs in the class, patients with active liver disease, severe renal dysfunction, and preexisting gallbladder disease. Fibric acids are excreted in breast milk and may interfere with infant lipid metabolism. Therefore, fibric acids are contraindicated in women who are breastfeeding. Fibric acids, as a class, are pregnancy category C. There is a documented case of a 30-year-old female who was placed on fenofibrate for the treatment of hypertriglyceridemia. The patient was on fenofibrate therapy for 1 year. Afterwards, it was discovered during a gynecologic visit that this patient had an unplanned pregnancy at 8 weeks gestation, and abruptly, fenofibrate therapy was discontinued. It is worth noting that the patient delivered a healthy male infant without congenital malformation.[4] However, fibric acids should only be considered in pregnancy if the benefit outweighs the risk of potential toxicity to the fetus; there is a lack of safety and efficacy data in the pediatric population, fenofibric acids are not recommended for use in pediatric patients with lipid disorders.[5]  Fibric acids may also interact with other drugs and may require dose or frequency adjustments. Monitoring and/or selection of a new therapy should also be considered in such cases. Rhabdomyolysis and myopathy have been reported when fibric acids are administered in combination with HMG-CoA reductase inhibitors or with colchicine, and in patients with hypothyroidism, diabetes mellitus, or renal failure. The only fibric acid that is FDA approved to be used in combination with an HMG-CoA reductase inhibitor (statin) is fenofibric acid. Combination therapy of gemfibrozil with repaglinide is also contraindicated.

Monitoring

Patients who start on fibric acid therapy require close monitoring for adverse effects. Fibric acids should only be a therapy consideration in patients being treated with low or moderate intensity statin therapy, if the benefits from reducing the risks of atherosclerotic cardiovascular disease or the benefits of reducing triglyceride levels, that are higher than 500 mg/dL, outweigh the potential risks of adverse effects. Monitoring parameters include a lipid profile, blood counts, and liver function tests. The treatment should cease if there is not an adequate response within 2 to 3 months of initiating fibric acid therapy. 

Toxicity

Management of an overdose of fibric acids is primarily symptomatic. Signs and symptoms of overdose may include increased CPK, abnormal liver function tests, abdominal pain, diarrhea, joint and muscle pain, nausea, and vomiting. Fibric acids are highly protein bound, which rules out the use of hemodialysis. Emesis or gastric lavage may be used in the case of fibric acid overdose so long as the usual precautions are observed to maintain the airway. 

Enhancing Healthcare Team Outcomes

The management of dyslipidemia requires input and interprofessional communication from members of the healthcare team including physicians, nurses, pharmacists, and other healthcare professionals. Without question, physicians and pharmacists need to be up to date on the guidelines detailing the management of blood cholesterol. Cholesterol is one of the primary risk factors for cardiovascular disease. Cardiovascular disease is one of the costliest disease states to manage, and in fact, the CDC estimated in 2010 that $444 billion, or $1 out of every $6 spent on health care, can be attributed to cardiovascular disease.[6] Physicians need to be able to manage dyslipidemia in the outpatient setting to prevent hospitalization due to cardiovascular disease. The role of the pharmacist is to verify orders for lipid-lowering agents and contact prescribers if there is a medication-related error. For instance, there are many commercially available lipid-lowering agents including HMG-CoA reductase inhibitors, niacin, bile acid sequestrants, and fibric acids. If the pharmacist receives an order and identifies a more suitable agent for the patient than the agent prescribed, then it is the responsibility of the pharmacist to contact the prescriber and relay that information.

In the hospital setting, nurses are tasked with several responsibilities including patient monitoring. For that reason, nurses need to have a basic understanding of the side effect profiles of commonly used lipid-lowering agents. In the case that a patient is suffering a medication-related adverse event, nurses are on the frontline to identify the problem and manage the patient's symptomatology. Additionally, adverse events should be reported to the medical team including physicians, nurse practitioners, and pharmacists so that appropriate action can be identified and initiated to control the patient's blood cholesterol. All members of the health care team play an important role in optimizing drug therapy for the patient, and the common denominator in the ideal scenario is interprofessional communication. In doing so, health care professionals can manage a patient's blood cholesterol in the outpatient setting, prevent unnecessary hospitalizations, and save the health care system billions of dollars in costs.


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Fibric Acid Antilipemic Agents - Questions

Take a quiz of the questions on this article.

Take Quiz
Which of the following is not a brand name for fibric acids?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following drug brands is the brand name for gemfibrozil?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following parameters does not need to be monitored during fibric acid therapy?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following antilipemic agents increase the activity of lipoprotein lipase?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is a branded name of fenofibrate?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is a brand name for fenofibric acid?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
For which drug should creatine phosphokinase (CPK) be monitored for when a patient experiences muscle aches?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
The following are antilipemic agents that are FDA approved to treat hypertriglyceridemia EXCEPT:



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 67-year-old male patient with a past medical history of hypertension, hyperlipidemia, type 2 diabetes mellitus, and gastroesophageal reflux disease presents for a follow-up with his primary care provider. The patient is currently taking amlodipine, lisinopril, rosuvastatin, insulin glargine, insulin lispro, and omeprazole. After his previous appointment, his provider ordered a blood test and noticed that the patient's triglycerides were elevated at 315 mg/dL. His clinician counseled him on lifestyle changes to combat the elevated triglycerides, including dietary modifications and moderate-intensity exercise several times throughout the week. Despite these changes, the patient's triglycerides remain elevated at 288 mg/dL. The patient and the provider decide to be more aggressive with treatment and start pharmacological therapy. Assuming the patient does not have renal insufficiency, which of the following is an appropriate drug, dose, and frequency to start the patient?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Fibric Acid Antilipemic Agents - References

References

Feingold KR,Grunfeld C, Triglyceride Lowering Drugs 2000;     [PubMed]
van Raalte DH,Li M,Pritchard PH,Wasan KM, Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharmaceutical research. 2004 Sep;     [PubMed]
Sunman H,Canpolat U,Sahiner L,Aytemir K, Use of fenofibrate during the first trimester of unplanned pregnancy in a patient with hypertriglyceridemia. The Annals of pharmacotherapy. 2012 Feb;     [PubMed]
Ling H,Luoma JT,Hilleman D, A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations. Cardiology research. 2013 Apr;     [PubMed]
Miller ML,Wright CC,Browne B, Lipid-lowering medications for children and adolescents. Journal of clinical lipidology. 2015 Sep-Oct;     [PubMed]
Hendrani AD,Adesiyun T,Quispe R,Jones SR,Stone NJ,Blumenthal RS,Martin SS, Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. World journal of cardiology. 2016 Feb 26;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of PA-Hospital Medicine. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for PA-Hospital Medicine, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in PA-Hospital Medicine, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of PA-Hospital Medicine. When it is time for the PA-Hospital Medicine board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study PA-Hospital Medicine.